ATE435663T1 - Krebstherapie mit einem nukleären rezeptorliganden und einem hdac-hemmer - Google Patents

Krebstherapie mit einem nukleären rezeptorliganden und einem hdac-hemmer

Info

Publication number
ATE435663T1
ATE435663T1 AT05717999T AT05717999T ATE435663T1 AT E435663 T1 ATE435663 T1 AT E435663T1 AT 05717999 T AT05717999 T AT 05717999T AT 05717999 T AT05717999 T AT 05717999T AT E435663 T1 ATE435663 T1 AT E435663T1
Authority
AT
Austria
Prior art keywords
nuclear receptor
cancer therapy
receptor ligand
hdac inhibitor
ligand
Prior art date
Application number
AT05717999T
Other languages
English (en)
Inventor
Moray James Campbell
Christopher Bunce
Lyndon Gommersall
Donna Peehl
Original Assignee
Univ Birmingham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Birmingham filed Critical Univ Birmingham
Application granted granted Critical
Publication of ATE435663T1 publication Critical patent/ATE435663T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT05717999T 2004-03-10 2005-03-10 Krebstherapie mit einem nukleären rezeptorliganden und einem hdac-hemmer ATE435663T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0405349.2A GB0405349D0 (en) 2004-03-10 2004-03-10 Cancer therapy and medicaments therefor
PCT/GB2005/000938 WO2005087206A2 (en) 2004-03-10 2005-03-10 Cancer therapy comprising a nuclear receptor ligand and a hdac inhibitor

Publications (1)

Publication Number Publication Date
ATE435663T1 true ATE435663T1 (de) 2009-07-15

Family

ID=32117372

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05717999T ATE435663T1 (de) 2004-03-10 2005-03-10 Krebstherapie mit einem nukleären rezeptorliganden und einem hdac-hemmer

Country Status (7)

Country Link
US (1) US20090105343A1 (de)
EP (1) EP1735002B1 (de)
AT (1) ATE435663T1 (de)
AU (1) AU2005221388B2 (de)
DE (1) DE602005015304D1 (de)
GB (1) GB0405349D0 (de)
WO (1) WO2005087206A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2644933A1 (en) * 2006-02-27 2007-09-07 Gilead Colorado, Inc. Combinations comprising a histone deacetylase inhibiting agent and a nuclear hormone receptor ligand for treating cardiovascular conditions
WO2007145704A2 (en) 2006-04-24 2007-12-21 Gloucester Pharmaceuticals Gemcitabine combination therapy
WO2007146730A2 (en) 2006-06-08 2007-12-21 Gloucester Pharmaceuticals Deacetylase inhibitor therapy
AU2007299920A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. PPAR Mediated Modulation of Neurogenesis
WO2008058287A1 (en) * 2006-11-10 2008-05-15 Syndax Pharmaceuticals, Inc. COMBINATION OF ERα+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER
AU2007342028B2 (en) * 2006-12-29 2013-06-13 Celgene Corporation Purifiction of romidepsin
NZ605526A (en) 2010-07-12 2015-04-24 Celgene Corp Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
CN107405325B (zh) 2015-02-06 2021-11-12 英特塞普特医药品公司 用于组合疗法的药物组合物
CN115068618B (zh) * 2022-07-11 2024-12-06 厦门大学附属第一医院 一种预防和/或治疗急性髓系白血病的联合用药物组合物及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262116B1 (en) * 1998-01-23 2001-07-17 Sloan-Kettering Institute For Cancer Research Transcription therapy for cancers
ATE346301T1 (de) * 1998-12-01 2006-12-15 Wrair Walter Reed Army Inst Of Diagnose von krebsstadium oder aggressivität
US20040266834A1 (en) * 1999-10-14 2004-12-30 Copland John A. Thiazolidinediones alone or in cabination with other therapeutic agents for cancer therapy
WO2002060430A1 (en) * 2001-02-01 2002-08-08 Cornell Research Foundation, Inc. Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors
US20040044028A1 (en) * 2001-03-30 2004-03-04 Obukowicz Mark G. Combinations of omega-3 fatty acids and cyclooxygenase-2 inhibitors for treatment or prevention of cardiovascular disease and treatment or prevention of cancer
US6656969B2 (en) * 2001-09-20 2003-12-02 Mayo Foundation For Medical Education And Research Methods and compositions for inhibiting the proliferation of prostate cancer cells

Also Published As

Publication number Publication date
DE602005015304D1 (de) 2009-08-20
GB0405349D0 (en) 2004-04-21
WO2005087206A3 (en) 2006-01-12
AU2005221388B2 (en) 2010-03-18
EP1735002A2 (de) 2006-12-27
WO2005087206A2 (en) 2005-09-22
EP1735002B1 (de) 2009-07-08
AU2005221388A1 (en) 2005-09-22
US20090105343A1 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
ATE435663T1 (de) Krebstherapie mit einem nukleären rezeptorliganden und einem hdac-hemmer
MY172012A (en) Use of dpp iv inhibitors
MY141119A (en) Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis
MX2013010770A (es) Tratamiento de tumores solidos.
CY1111547T1 (el) Συνδυασμος zd6474 και πεμετρεξεδης
EA200900912A1 (ru) Специфическая терапия и лекарственное средство на основе интегриновых лигандов для лечения рака
UA86586C2 (ru) Комбинация для лечения заболеваний, связанных с клеточной пролиферацией, миграцией или апоптозом клеток миеломы или с ангиогенезом
CY1111482T1 (el) Συνδυασμος azd2171 και πεμετρεξεδης
MX2007003505A (es) Combinacion que comprende zd6474 e imatinib.
RU2013131241A (ru) Композиции, содержащие ингибитор рi3к и ингибитор мек, а также их применение для лечения рака
NO20044498L (no) Kombinasjonsterapi for behandling av cancer
ATE409039T1 (de) Kombinationstherapie gegen krebserkrankungen mit azd2171 und zd1839
NO20064755L (no) Kombinasjonsterapi
NO20064754L (no) Kombinasjonsterapi
NO20064753L (no) Kombinasjonsterapi
NO20056171L (no) Kombinasjonsterapi
TW200724158A (en) Combination therapy in the treatment of cancer
NO20043774L (no) The use of devazenide as analgesic agent
UA110795C2 (uk) Спосіб лікування раку підшлункової залози
ATE339209T1 (de) Kombinationstherapie mit gemzitabin und zd6126

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties